Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study
Clinical Gastroenterology and Hepatology · 2023
DOI: 10.1016/j.cgh.2023.01.002 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Gastroenterology and Hepatology, 2023. Verfasst von Ariela K Holmer und 24 weiteren Autor:innen. Beteiligte Einrichtung: Division of Gastroenterology, New York University Langone Health, New York, New York; Division of Gastroenterology, University of California San Dieg…. Hauptthemen laut MEDLINE: Inflammatory Bowel Diseases, Neoplasms, Biological Products. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 20 Literaturangaben. Gefördert von: NIDDK NIH HHS, Takeda Pharmaceuticals U.S.A., Janssen Pharmaceuticals.
Abstract (Originalsprache)
BACKGROUND & AIMS: Safety of biologic agents is a key consideration in patients with inflammatory bowel disease (IBD) and active or recent cancer. We compared the safety of tumor necrosis factor (TNF)-α antagonists vs non-TNF biologics in patients with IBD with active or recent cancer. METHODS: We conducted a multicenter retrospective cohort study of patients with IBD and either active cancer (cohort A) or recent prior cancer (within ≤5 years; cohort B) who were treated with TNFα antagonists or non-TNF biologics after their cancer diagnosis. Primary outcomes were progression-free survival (cohort A) or recurrence-free survival (cohort B). Safety was compared using inverse probability of treatment weighting with propensity scores. RESULTS: In cohort A, of 125 patients (483.8 person-years of follow-up evaluation) with active cancer (age, 54 ± 15 y, 75% solid-organ malignancy), 10 of 55 (incidence rate [IR] per 100 py, 4.4) and 9 of 40 (IR, 10.4) patients treated with TNFα antagonists and non-TNF biologics had cancer progression, respectively. There was no difference in the risk of progression-free survival between TNFα antagonists vs non-TNF biologics (hazard ratio, 0.76; 95% CI, 0.25-2.30). In cohort B, of 170 patients (513 person-years of follow-up evaluation) with recent prior cancer (age, 53 ± 15 y, 84% solid-organ malignancy; duration of remission, 19 ± 19 mo), 8 of 78 (IR, 3.4) and 5 of 66 (IR 3.7) patients treated with TNFα antagonists and non-TNF biologics had cancer recurrence, respectively. The risk of recurrence-free survival was similar between both groups (hazard ratio, 0.94; 95% CI, 0.24-3.77). CONCLUSIONS: In patients with IBD with active or recent cancer, TNFα antagonists and non-TNF biologics have comparable safety. The choice of biologic should be dictated by IBD disease severity in collaboration with an oncologist.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Gastroenterology, New York University Langone Health, New York, New York; Division of Gastroenterology, University of California San Diego, La Jolla, California. Electronic address: ariela.holmer@nyulangone.…
- Division of Biostatistics and Bioinformatics, Department of Family Medicine and Public Health, University of California San Diego, La Jolla, California.
- Division of Gastroenterology, University of Alabama at Birmingham, Birmingham, Alabama.
- Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, New York.
- Division of Gastroenterology, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania.
- Division of Gastroenterology, Case Western Reserve University, Cleveland, Ohio.
Förderung
- NIDDK NIH HHS
- Takeda Pharmaceuticals U.S.A.
- Janssen Pharmaceuticals
- National Institutes of Health
- Crohn's and Colitis Foundation
- National Institute of Diabetes and Digestive and Kidney Diseases
Zitieren
APA
Holmer, A. K., Luo, J., Russ, K. B., Park, S., Yang, J. Y., Ertem, F., Dueker, J., Nguyen, V., Hong, S., Zenger, C., Axelrad, J. E., Sofia, A., Petrov, J. C., Al-Bawardy, B., Fudman, D. I., Llano, E., Dailey, J., Jangi, S., Khakoo, N., …, & Rising Educators Academics and Clinicians Helping-IBD (REACH-IBD) (2023). Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clinical Gastroenterology and Hepatology. https://doi.org/10.1016/j.cgh.2023.01.002
Vancouver
Holmer AK, Luo J, Russ KB, Park S, Yang JY, Ertem F, et al. Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study. Clinical Gastroenterology and Hepatology. 2023. doi:10.1016/j.cgh.2023.01.002
BibTeX
@article{Holmer2023,
author = {Holmer, Ariela K and Luo, Jiyu and Russ, Kirk B and Park, Sarah and Yang, Jeong Yun and Ertem, Furkan and Dueker, Jeffrey and Nguyen, Vu and Hong, Simon and Zenger, Cameron and Axelrad, Jordan E and Sofia, Anthony and Petrov, Jessica C and Al-Bawardy, Badr and Fudman, David I and Llano, Ernesto and Dailey, Joseph and Jangi, Sushrut and Khakoo, Nidah and Damas, Oriana M and Barnes, Edward L and Scott, Frank I and Ungaro, Ryan C and Singh, Siddharth and Rising Educators Academics and Clinicians Helping-IBD (REACH-IBD), Rising Educators Academics and Clinicians Helping-IBD (REACH-IBD)},
title = {Comparative Safety of Biologic Agents in Patients With Inflammatory Bowel Disease With Active or Recent Malignancy: A Multi-Center Cohort Study},
journal = {Clinical Gastroenterology and Hepatology},
year = {2023},
doi = {10.1016/j.cgh.2023.01.002}
}
EUVIMED